Alterity confirms ATH434 Phase 3 path, secures U.S. patent protection through 2045
AI Summary- Alterity received FDA agreement on ATH434’s Phase 3 design and MSA registrational pathway.
- Approximately 200 patients will receive ATH434 50 mg or placebo twice daily for 12 months.
- Alterity held A$41.3 million in cash and equivalents on September 30, 2026.